Promise of neoral C2, basiliximab, and everolimus in lung transplantation

Transplantation Proceedings

Volumn 36, Issue 2 SUPPL., 2004, Pages S509-S513

  Poirier, C D ^a  

^a NOTRE DAME HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMITOTIC AGENT; AZATHIOPRINE; BASILIXIMAB; CYCLOSPORIN A; EVEROLIMUS; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; STEROID; THYMOCYTE ANTIBODY; CYCLOSPORIN; DRUG DERIVATIVE; HYBRID PROTEIN;

AREA UNDER THE CURVE; B LYMPHOCYTE; BLOOD SAMPLING; CELL PROLIFERATION; CLINICAL TRIAL; CYSTIC FIBROSIS; DIGESTIVE SYSTEM INFLAMMATION; DOSE RESPONSE; DRUG ABSORPTION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG MEGADOSE; DRUG MONITORING; GRAFT REJECTION; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; KIDNEY GRAFT; LIVER TRANSPLANTATION; LOW DRUG DOSE; LUNG TRANSPLANTATION; LYMPHOCYTE COUNT; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SURVIVAL RATE; T LYMPHOCYTE; GRAFT SURVIVAL; IMMUNOLOGY;

ANTIBODIES, MONOCLONAL; AREA UNDER CURVE; CYCLOSPORINE; GRAFT SURVIVAL; HUMANS; LUNG TRANSPLANTATION; RECOMBINANT FUSION PROTEINS; SIROLIMUS;

EID: 1642378787     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2004.01.045     Document Type: Article

References (24)

1. Hertz M.I., Mohacsi P.J., Taylor D.O., et al. The registry of the International Society for Heart and Lung Transplantation introduction to the Twentieth Annual Reports - 2003. J Heart Lung Transplant. 22:2003;610.
2. Arcasoy S.M., Kotloff R.M. Lung transplantation. N Engl J Med. 340:1999;1081.
3. Kahan B.D., Koch S.M. Current immunosuppressant regimens considerations for critical care. Curr Opin Crit Care. 7:2001;242.
4. Levy G., Thervet E., Lake J., et al. Patient management by Neoral C(2) monitoring an international consensus statement. Transplantation. 73:2002;S12.
5. Cantarovich M., Besner J.G., Barkun J.S., et al. Two-hour cyclosporine level determination is the appropriate tool to monitor Neoral therapy. Clin Transplant. 12:1998;243.
6. Campbell S.B., Johnson D.W. Patient management by cyclosporine C2 monitoring not enough science yet to justify the practice. Transplantation. 75:2003;1917.
7. Trull A., Steel L., Sharples L., et al. Randomized, trough blood cyclosporine concentration-controlled trial to compare the pharmacodynamics of Sandimmune and Neoral in de novo lung transplant recipients. Ther Drug Monit. 21:1999;17.
8. Dumont R.J., Partovi N., Levy R.D., et al. A limited sampling strategy for cyclosporine area under the curve monitoring in lung transplant recipients. J Heart Lung Transplant. 20:2001;897.
9. Knoop C., Vervier I., Thiry P., et al. Cyclosporine pharmacokinetics and dose monitoring after lung transplantation comparison between cystic fibrosis and other conditions. Transplantation. 76:2003;683.
10. Nashan B., Moore R., Amlot P., et al. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group. Lancet. 350:1997;1193.
11. Kahan B.D., Rajagopalan P.R., Hall M. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group. Transplantation. 67:1999;276.
12. Sheashaa H.A., Bakr M.A., Ismail A.M., et al. Basiliximab reduces the incidence of acute cellular rejection in live-related-donor kidney transplantation a three-year prospective randomized trial. J Nephrol. 16:2003;393.
13. Neuhaus P., Clavien P.A., Kittur D., et al. Improved treatment response with basiliximab immunoprophylaxis after liver transplantation results from a double-blind randomized placebo-controlled trial. Liver Transpl. 8:2002;132.
14. Hausen B., Gummert J., Berry G.J., et al. Prevention of acute allograft rejection in nonhuman primate lung transplant recipients induction with chimeric anti-interleukin-2 receptor monoclonal antibody improves the tolerability and potentiates the immunosuppressive activity of a regimen using low doses of both microemulsion cyclosporine and 40-O-(2-hydroxyethyl)- rapamycin. Transplantation. 69:2000;488.
15. Gerbase M.W., de Perrot M., Spiliopoulos A., et al. Selective monoclonal versus polyclonal antibodies for induction of immunosuppression in lung recipients. Clin Pharmacol Ther. 72:2002;103.
16. Moreno A., Maestre J., Balcells J., et al. Lung transplantation in young infants with interstitial pneumonia. Transplant Proc. 35:2003;1951.
17. Nashan B. Review of the proliferation inhibitor everolimus. Expert Opin Investig Drugs. 11:2002;1845.
18. Serkova N., Jacobsen W., Niemann C.U., et al. Sirolimus, but not the structurally related RAD (everolimus), enhances the negative effects of cyclosporine on mitochondrial metabolism in the rat brain. Br J Pharmacol. 133:2001;875.
19. Kahan B.D., Kaplan B., Lorber M.I., et al. RAD in de novo renal transplantation comparison of three doses on the incidence and severity of acute rejection. Transplantation. 71:2001;1400.
20. Vitko S, Whelchel J, Eris J, et al: Excellent graft function in de novo kidney transplant recipients treated with everolimus, reduced dose Neoral and Simulect: 6 month analysis. American Transplant Congress, June 1-4, 2003, Washington, DC
21. Hausen B., Ikonen T., Briffa N., et al. Combined immunosuppression with cyclosporine (neoral) and SDZ RAD in non-human primate lung transplantation systematic pharmacokinetic-based trials to improve efficacy and tolerability. Transplantation. 69:2000;76.
22. Valentine VG, Love RB, Snell GI, et al: Multicenter, randomized, double-blind study of everolimus (RAD) vs azathioprine to inhibit the decline of pulmonary function in stable lung transplant recipients - one-year results. American Transplant Congress, June 1-4, 2003, Washington, DC
23. Alho H.S., Salminen U.S., Maasilta P.K., et al. Epithelial apoptosis in experimental obliterative airway disease after lung transplantation. J Heart Lung Transplant. 22:2003;1014.
24. Eisen H.J., Tuzcu E.M., Dorent R., et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med. 349:2003;847.